The toxicity of troglitazone, roziglitazone and vitamin e in human hep g2 hepatoma cells

Ball, A.J. and Tettey, J.N.A. and Grant, M.H. (2004) The toxicity of troglitazone, roziglitazone and vitamin e in human hep g2 hepatoma cells. Toxicology, 194 (3). pp. 250-251. ISSN 0300-483X

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

Troglitazone (TGZ), a member of the thiazolidinedione class of drugs used to treat type-II diabetes, has been associated with hepatotoxicity (Biswas et al., 2001). TGZ differs structurally from the newer non-hepatotoxic glitazone, rosiglitazone (RGZ), in that it contains the chromanol moiety of Vitamin E (Vit E). This study compares the toxicity of TGZ, RGZ and Vit E in human HepG2 cells